Publicaciones en colaboración con investigadores/as de Hospital Universitari de Bellvitge (14)

2022

  1. Experts document on methotrexate use in combined therapy with biological or targeted synthetic disease modifying drugs in patients with rheumatoid arthritis

    Reumatologia Clinica, Vol. 18, Núm. 1, pp. 33-41

2021

  1. Cardiovascular mortality and cardiovascular event rates in patients with inflammatory rheumatic diseases in the CARdiovascular in rheuMAtology (CARMA) prospective study-results at 5 years of follow-up

    Rheumatology (Oxford, England), Vol. 60, Núm. 6, pp. 2906-2915

  2. Dietary habits in patients with fibromyalgia: a cross-sectional study

    Clinical and experimental rheumatology, Vol. 39, Núm. 3, pp. 170-173

  3. Food groups associated with immune-mediated inflammatory diseases: a Mendelian randomization and disease severity study

    European Journal of Clinical Nutrition, Vol. 75, Núm. 9, pp. 1368-1382

2020

  1. Efficacy and safety of glucocorticoids in rheumatoid arthritis: Systematic literature review

    Reumatologia Clinica, Vol. 16, Núm. 3, pp. 222-228

  2. Expert Recommendations on the Interleukin 6 Blockade in Patients with Rheumatoid Arthritis

    Reumatologia Clinica, Vol. 16, Núm. 4, pp. 272-281

2019

  1. Incidence of first cardiovascular event in Spanish patients with inflammatory rheumatic diseases: prospective data from the CARMA project

    Clinical and experimental rheumatology, Vol. 37, Núm. 5, pp. 731-739

2018

  1. Recommendations for the use of parenteral methotrexate in rheumatic diseases

    Reumatologia Clinica, Vol. 14, Núm. 3, pp. 142-149

2017

  1. Diagnostic Value and Validity of Early Spondyloarthritis Features: Results From a National Spanish Cohort

    Arthritis Care and Research, Vol. 69, Núm. 6, pp. 938-942

  2. Lipoprotein(a) concentrations in rheumatoid arthritis on biologic therapy: Results from the CARdiovascular in rheuMAtology study project

    Journal of Clinical Lipidology, Vol. 11, Núm. 3, pp. 749-756.e3

2015

  1. Actualización 2014 del Documento de Consenso de la Sociedad Española de Reumatología sobre el uso de terapias biológicas en la artritis reumatoide

    Reumatologia Clinica, Vol. 11, Núm. 5, pp. 279-294

2014

  1. PDE3A-SLCO1C1 locus is associated with response to anti-tumor necrosis factor therapy in psoriatic arthritis

    Pharmacogenomics, Vol. 15, Núm. 14, pp. 1763-1769

2011

  1. Consenso SER sobre la gestión de riesgo del tratamiento con terapias biológicas en pacientes con enfermedades reumáticas

    Reumatologia Clinica, Vol. 7, Núm. 5, pp. 284-298

2007

  1. Registro Español de Acontecimientos Adversos de Terapias Biológicas en Enfermedades Reumáticas (BIOBADASER): Informe de la situación, 26 de enero de 2006

    Reumatologia Clinica, Vol. 3, Núm. 1, pp. 4-20